ODDIFACT
Oddifact SAS develops and licenses orphan drug designations (ODDs) and applies an internal AI platform to identify repurposing opportunities for rare diseases. The company integrates regulatory, market-access and commercialization activities to collaborate with manufacturers and laboratories on bringing biotherapy-based solutions and research outputs to patients. It also offers purchasable research products and consumer supplements through an online store.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Clinical Trial Data Analysis Report
Comprehensive report on clinical trial data analysis offered as a purchasable product.
Drug Interaction Research Paper
In-depth research paper on drug interactions offered for purchase.
Digestive Health Probiotics
Probiotic supplement marketed for digestive health.
Allergy Relief Tablets
Non-drowsy allergy relief tablets sold via the online store.
Omega-3 Fish Oil Softgels
Omega-3 supplement marketed for general health.
Protein Powder Blend
Protein supplement offered via the online storefront.
Clinical Trial Data Analysis Report
Comprehensive report on clinical trial data analysis offered as a purchasable product.
Drug Interaction Research Paper
In-depth research paper on drug interactions offered for purchase.
Digestive Health Probiotics
Probiotic supplement marketed for digestive health.
Allergy Relief Tablets
Non-drowsy allergy relief tablets sold via the online store.
Omega-3 Fish Oil Softgels
Omega-3 supplement marketed for general health.
Protein Powder Blend
Protein supplement offered via the online storefront.
Services
Development and licensing of orphan drug designations and support to obtain ODD status.
Application of an AI platform to search academic research and prioritize biologics for repurposing to rare-disease indications.
Support integrating regulatory specifics and accelerating dossier development steps ahead of submission.
Preparation and sale of comprehensive clinical trial data analysis reports.
In-depth drug–drug interaction research papers available for purchase.
Services to connect identified candidates with manufacturers and laboratories, and to structure supply agreements.
Development and licensing of orphan drug designations and support to obtain ODD status.
Application of an AI platform to search academic research and prioritize biologics for repurposing to rare-disease indications.
Support integrating regulatory specifics and accelerating dossier development steps ahead of submission.
Preparation and sale of comprehensive clinical trial data analysis reports.
In-depth drug–drug interaction research papers available for purchase.
Services to connect identified candidates with manufacturers and laboratories, and to structure supply agreements.
Expertise Areas
- AI-driven drug repurposing
- Orphan drug designation development
- Regulatory dossier preparation and submission support
- Clinical data analysis and reporting
Key Technologies
- Artificial intelligence for biomedical literature search
- Machine learning model iteration and continuous improvement
- Clinical trial data analysis tools
- Regulatory dossier generation workflows
News & Updates
Video discussion linked from the company news section referencing a Davos 2025 appearance.
FDA granted an orphan drug designation for infliximab for the indication of Kawasaki disease in children.
FDA granted an orphan drug designation for rituximab for ITP.
FDA granted an orphan drug designation for adalimumab for Takayasu arteritis.
FDA granted an orphan drug designation for rituximab for IIM.
FDA granted an orphan drug designation for rituximab for AHA.
Video discussion linked from the company news section referencing a Davos 2025 appearance.
FDA granted an orphan drug designation for infliximab for the indication of Kawasaki disease in children.
FDA granted an orphan drug designation for rituximab for ITP.
FDA granted an orphan drug designation for adalimumab for Takayasu arteritis.
FDA granted an orphan drug designation for rituximab for IIM.
FDA granted an orphan drug designation for rituximab for AHA.